Impact BioMedical (IBO) Registration Filing summary

Management team and governance

• CEO and President is Frank D. Heuszel, who also serves as Chairman of the Board.

• Other key officers include Jason Grady (Director), Todd D. Macko (Chief Financial Officer), Mark Suseck (Chief Operating Officer), and Dr. Elise Brownell (Director).

• Additional directors are Melissa Sims, Castel Hibbert, Christian Zimmerman, and David Keene.

Offering details and pricing

• Registration statement filed as Form S-1 Amendment No. 7, with securities to be offered as soon as practicable after effectiveness.

• Securities may be offered on a delayed or continuous basis under Rule 415.

• Registrant is a non-accelerated filer, smaller reporting company, and emerging growth company.

Use of proceeds and capital allocation

• Estimated total expenses for issuance and distribution are $252,000, including SEC, FINRA, NYSE American listing, legal, accounting, transfer agent, and miscellaneous fees.